STAT3 and breast cancer: The inhibitory effect of ODZ10117 on tyrosine-phosphorylated STAT3 was greater than the known inhibitors in breast cancer cells that are persistently activated or activated by IL-6-stimulation (Figure 4H and Supplementary Figure S9C–E).